Cover Image
市場調查報告書

可溶性鳥甘酸環化酶:開發中產品分析

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365802
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
可溶性鳥甘酸環化酶:開發中產品分析 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 89 Pages
簡介

本報告提供以可溶性鳥甘酸環化酶為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

可溶性鳥甘酸環化酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ironwood Pharmaceuticals, Inc.
  • Mallinckrodt Plc
  • NicOx S.A.
  • SynZyme Technologies, LLC

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0322TDB

Summary

Global Markets Direct's, 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016', provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Overview
  • Therapeutics Development
    • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Stage of Development
    • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Therapy Area
    • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Indication
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Companies
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Universities/Institutes
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Ironwood Pharmaceuticals, Inc.
    • Mallinckrodt Plc
    • NicOx S.A.
    • SynZyme Technologies, LLC
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
    • A-8R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY sGCact - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY sGCstim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-703704 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyurea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-1701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IW-1973 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IWP-953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naproxcinod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-1021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-422 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-429 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-466 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-470 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-667 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • riociguat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Platelet Aggregation for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vacno - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vericiguat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Projects
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
  • Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Featured News & Press Releases
    • May 13, 2016: Bayer to Present Pulmonary Hypertension Data at American Thoracic Society 2016 International Conference
    • May 12, 2016: Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias
    • Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences
    • Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IWP-953 at Upcoming Scientific Conferences
    • Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701
    • Nov 06, 2015: Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA
    • Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1973
    • Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1701
    • Oct 30, 2015: Mallinckrodt's INOmax Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery
    • Oct 22, 2015: Bayer to Present Pulmonary Arterial Hypertension Data at American College of Chest Physicians Annual Meeting
    • Oct 07, 2015: Bayer to Evaluate Riociguat in Children Suffering from Pulmonary Arterial Hypertension
    • Jul 22, 2015: Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973
    • Jun 23, 2015: Novoteris Announces $2.8 Million Award from Cystic Fibrosis Foundation Therapeutics to Support Development of Inhaled Nitric Oxide Antimicrobial Therapy
    • May 15, 2015: Bayer to Present Data on Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension at ATS 2015 International Conference
    • May 11, 2015: Promising preclinical data on NCX 667 for glaucoma presented at ARVO by Nicox
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Bayer AG, H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016
  • Pipeline by Mallinckrodt Plc, H1 2016
  • Pipeline by NicOx S.A., H1 2016
  • Pipeline by SynZyme Technologies, LLC, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Dormant Projects (Contd..4), H1 2016
  • Dormant Projects (Contd..5), H1 2016
  • Dormant Projects (Contd..6), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top